Pharmaceuticals
10 biomarker development experts
These ten professionals have led biomarker development inside drug developers, with titles such as senior director of biomarker development and head of clinical biomarkers. A reader can learn how in-house biomarker teams plan, build and use biomarkers in clinical programs.
Professionals to explore
01—10Alvydas Mikulskis
LinkedInExperience: Director Bioanalytical and Biomarker Development · Takeda
Former Director Bioanalytical and Biomarker Development at Takeda (2018–2019), and Senior Director Biomarkers & Imaging at Vertex Pharmaceuticals since 2021. Former Director, Clinical Biomarkers & Imaging at Vertex (2019–2021). The profile describes hands-on development, transfer to CROs, validation and support of bioanalytical and biomarker assays from early to late stage clinical development.
Gianluca Quintini
LinkedInExperience: Senior Director of Biomarker Development and Translational Science · CureVac
Senior Director of Biomarker Development and Translational Science at CureVac since 2018. Former Associate Director Applied Clinical Biology at Dr. Reddy's Laboratories (2014–2018), Principal Scientist Biomarkers at Takeda (2012–2014) and Biomarker Specialist at Nycomed GmbH (2010–2012). The profile lists experience in assay development.
Lindsay King
LinkedInExperience: Executive Director, Head of Clinical and Translational Biomarkers · Pfizer
Executive Director, Head of Clinical and Translational Biomarkers at Pfizer since 2025. Former Senior Director, Biomarker Head, Clinical Bioanalytics, Translational Clinical Sciences (2023–2025), Senior Director, Biomarker Clinical Assay Team Lead (2021–2022) and Director, Biomarker Clinical Assay Team Lead (2020–2021) at Pfizer.
Mary Birchler
LinkedInExperience: Director, Biomarker and Bioanalytical Platforms · GSK
Director, Biomarker and Bioanalytical Platforms at GSK since 2024, where the profile says this person leads the group responsible for delivering validated ligand-binding biomarker assays to support clinical programs. Former Associate Director (2019–2024) and Investigator Group Leader, Exploratory Biomarkers (2017–2019) at GSK.
Meghna Das Thakur
LinkedInExperience: Director, Oncology Biomarker Sciences · Gilead Sciences
Former Director, Oncology Biomarker Sciences at Gilead Sciences (2022–2024), and Senior Director, Biomarker Sciences and Diagnostics there since 2024. Former Senior Principal Scientist at Genentech (2014–2022). The profile describes expertise in the design and execution of clinical biomarker strategies and in validating predictive biomarkers.
Mirella E Lazarov
LinkedInExperience: AVP, Head of Clinical Biomarkers and Diagnostics · Amgen
AVP, Head of Clinical Biomarkers and Diagnostics at Amgen since 2020. Former Head, Companion Diagnostics Center of Excellence at AbbVie (2016–2020), Senior Director Biology, Head of Biomarkers at Gilead Sciences (2011–2014), and Senior Global Clinical Biomarker Leader, Biomarker Lead for the Oncology Signaling Franchise at Genentech (2009–2011).
Ramakrishna Boyanapalli
LinkedInExperience: Senior Director, Biomarker Development · Bristol Myers Squibb
Senior Director, Biomarker Development at Bristol Myers Squibb since 2022, which the profile headline places in Translational & Biomarker Development, Neurology TRC. The profile describes a focus on biomarker strategy, assay development and validations. Former Senior Director (2021–2022) and Director (2019–2021) at Wave Life Sciences.
Tripti Gaur
LinkedInExperience: Biomarkers and Companion Diagnostics Lead · AVEO Oncology
Biomarkers and Companion Diagnostics Lead at AVEO Oncology since 2025, where the profile lists strategic leadership to develop and implement biomarker development plans and define patient selection and companion diagnostic strategies. Former Associate Director and Biomarker Lead, Clinical Biomarkers and Exploratory Research at CRISPR Therapeutics (2019–2020).
Vaishali Shinde
LinkedInExperience: Senior Director, Translational & Clinical Assay Lead · Corbus Pharmaceuticals
Senior Director, Translational & Clinical Assay Lead at Corbus Pharmaceuticals since 2023, and former Director, Translational & Clinical Assay Lead there (2022–2023). The profile says this person is currently leading translational and clinical biomarker strategies and managing biomarker related activities. Former Associate Director & Head of Molecular Pathology Group at Takeda (2020–2022).
Yanmei Lu
LinkedInExperience: Vice President, Biomarker and BioAnalytical Sciences · Sangamo Therapeutics, Inc.
Vice President, Biomarker and BioAnalytical Sciences at Sangamo Therapeutics, Inc. since 2021, and former Sr. Director, Biomarker and BioAnalytical Sciences there (2018–2020). Former Scientist at Genentech (2003–2018). The profile describes work advancing gene therapies, cell therapies and biologics, with expertise that spans translational biomarker strategy.
Choose the right perspective
Match the person's setting to yours, since standing up biomarker work at a small biotech differs from running a clinical biomarker group at a large drug maker. Also decide whether your question is mainly about biomarker strategy, assay development and validation or companion diagnostics, and pick someone whose roles centered on that work.
Questions to take into the conversation
- 01How do you decide which biomarkers are worth validating before a trial starts?
- 02How do you take a biomarker assay from research use to a validated assay for clinical samples?
- 03When should a program plan for a companion diagnostic, and how does that change the biomarker work?
Reaching biomarker development experts
How can I contact one of these biomarker development experts?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 10 companies, including Takeda, CureVac and Pfizer, based on profile data retrieved on October 4, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach biomarker development experts?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal